Environmental or self-antigens and homotypic interactions cause BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other alerts from the microenvironment and increasing the activation of anti-apoptotic and proliferation pathways.Duvelisib was the next PI3K inhibitor authorized by the FDA, also based upon a section I